Shenzhen New Industries Biomedical Engineering (300832) Q1 2026 earnings summary

Executive summary

• Achieved Q1 revenue of ¥1,128.59 million, up 0.34% year-over-year; net profit attributable to shareholders rose 1.02% to ¥441.99 million.

• Domestic main business revenue declined 1.85% year-over-year, with reagent sales up 9.64% but instrument sales down due to longer revenue recognition cycles.

• Overseas main business revenue grew 3.33% year-over-year; overseas reagent sales surged 22.49%, while instrument sales declined due to Middle East conflicts and logistics disruptions.

• High-end equipment sales remained strong, with 276 MAGLUMI X8/X10 units and 62 SATLARS T8 automation lines sold in Q1.

• Excluding FX losses, total profit grew 13.16% year-over-year.

Financial highlights

• Operating cash flow reached ¥358.97 million, a 1,835.90% increase year-over-year, driven by higher sales collections and lower payments.

• Total assets at quarter-end were ¥10,216.23 million, up 2.77% from year-end; shareholders’ equity rose 3.74% to ¥9,486.70 million.

• Basic and diluted EPS were ¥0.5625, up from ¥0.5568 year-over-year.

• Gross margin remained stable; total profit margin improved due to cost control and product mix.

Outlook and guidance

• Full-year automation line installation/sales target is on track, supported by strong Q1 performance.

• Continued focus on high-end equipment and overseas market expansion.